Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
4.920
-0.100 (-1.99%)
Apr 29, 2026, 11:56 AM EDT - Market open
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
70
Market Cap
1.25B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 1.12B |
| AbCellera Biologics | 75.13M |
| Viridian Therapeutics | 70.85M |
| Wave Life Sciences | 42.73M |
| Precigen | 9.68M |
| DBV Technologies | 5.64M |
SVRA News
- 11 days ago - Savara Announces New Employment Inducement Grant - Business Wire
- 13 days ago - Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 15 days ago - Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference - Business Wire
- 22 days ago - Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 4 weeks ago - Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire
- 6 weeks ago - Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - Business Wire
- 7 weeks ago - Savara Transcript: The Citizens Life Sciences Conference 2026 - Transcripts
- 7 weeks ago - Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Business Wire